Xencor Inc (NASDAQ:XNCR) – Research analysts at Wedbush lowered their Q2 2019 earnings estimates for Xencor in a report released on Tuesday, May 14th. Wedbush analyst D. Nierengarten now anticipates that the biopharmaceutical company will post earnings of ($0.50) per share for the quarter, down from their previous forecast of ($0.39). Wedbush also issued estimates for Xencor’s Q3 2019 earnings at ($0.51) EPS, Q4 2019 earnings at ($0.54) EPS, FY2020 earnings at ($0.77) EPS, FY2021 earnings at ($2.28) EPS, FY2022 earnings at ($1.83) EPS and FY2023 earnings at $1.09 EPS.
Several other equities analysts have also recently commented on the company. Cantor Fitzgerald reiterated a “buy” rating and set a $40.00 target price on shares of Xencor in a research note on Tuesday, February 5th. BidaskClub cut Xencor from a “hold” rating to a “sell” rating in a research note on Friday, February 22nd. Nomura cut Xencor from a “neutral” rating to a “reduce” rating and reduced their target price for the company from $28.00 to $21.00 in a research note on Friday, February 22nd. Piper Jaffray Companies increased their target price on Xencor to $56.00 and gave the company an “overweight” rating in a research note on Tuesday, February 26th. Finally, ValuEngine cut Xencor from a “strong-buy” rating to a “buy” rating in a research note on Thursday, February 28th. Two research analysts have rated the stock with a sell rating, one has issued a hold rating and nine have given a buy rating to the stock. Xencor has a consensus rating of “Buy” and a consensus target price of $41.49.
NASDAQ XNCR opened at $34.22 on Friday. The company has a market capitalization of $1.96 billion, a price-to-earnings ratio of -26.12 and a beta of 1.35. Xencor has a fifty-two week low of $27.75 and a fifty-two week high of $48.38. The company has a debt-to-equity ratio of 0.02, a current ratio of 6.66 and a quick ratio of 6.66.
Xencor (NASDAQ:XNCR) last posted its earnings results on Thursday, May 9th. The biopharmaceutical company reported $1.38 earnings per share (EPS) for the quarter, topping the Zacks’ consensus estimate of $0.43 by $0.95. The business had revenue of $111.94 million for the quarter, compared to analyst estimates of $60.05 million.
Hedge funds and other institutional investors have recently modified their holdings of the business. Vanguard Group Inc. increased its holdings in shares of Xencor by 33.0% during the third quarter. Vanguard Group Inc. now owns 4,195,674 shares of the biopharmaceutical company’s stock valued at $163,506,000 after purchasing an additional 1,040,578 shares during the period. Norges Bank acquired a new position in shares of Xencor during the fourth quarter valued at $28,271,000. Sofinnova Investments Inc. acquired a new position in shares of Xencor during the fourth quarter valued at $7,221,000. Dimensional Fund Advisors LP increased its holdings in shares of Xencor by 42.6% during the fourth quarter. Dimensional Fund Advisors LP now owns 399,186 shares of the biopharmaceutical company’s stock valued at $14,432,000 after purchasing an additional 119,347 shares during the period. Finally, Rhenman & Partners Asset Management AB increased its holdings in shares of Xencor by 49.2% during the first quarter. Rhenman & Partners Asset Management AB now owns 325,965 shares of the biopharmaceutical company’s stock valued at $10,124,000 after purchasing an additional 107,428 shares during the period. 84.73% of the stock is currently owned by hedge funds and other institutional investors.
In related news, major shareholder John S. Stafford III bought 38,300 shares of the company’s stock in a transaction on Friday, March 15th. The shares were purchased at an average cost of $29.02 per share, with a total value of $1,111,466.00. The acquisition was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. Also, major shareholder John S. Stafford III bought 1,100 shares of the company’s stock in a transaction on Monday, March 18th. The stock was bought at an average cost of $29.90 per share, for a total transaction of $32,890.00. The disclosure for this purchase can be found here. Insiders have purchased 61,511 shares of company stock worth $1,804,827 over the last 90 days. 4.70% of the stock is currently owned by company insiders.
Xencor, Inc, a clinical stage biopharmaceutical company, focuses on the discovery and development of engineered monoclonal antibody and other protein therapeutics to treat severe and life threatening diseases with unmet medical needs. It develops its antibody product candidates to treat autoimmune and allergic diseases, cancer, and other conditions.
Recommended Story: Why are percentage gainers important?
Receive News & Ratings for Xencor Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Xencor and related companies with MarketBeat.com's FREE daily email newsletter.